Ironwood Pharmaceuticals (IRWD) Non-Current Receivables: 2018-2022
Historic Non-Current Receivables for Ironwood Pharmaceuticals (IRWD) over the last 3 years, with Dec 2022 value amounting to $14.6 million.
- Ironwood Pharmaceuticals' Non-Current Receivables fell 39.21% to $14.6 million in Q4 2022 from the same period last year, while for Dec 2022 it was $14.6 million, marking a year-over-year decrease of 39.21%. This contributed to the annual value of $14.6 million for FY2022, which is 39.21% down from last year.
- According to the latest figures from Q4 2022, Ironwood Pharmaceuticals' Non-Current Receivables is $14.6 million, which was up 1.04% from $14.4 million recorded in Q3 2022.
- Ironwood Pharmaceuticals' Non-Current Receivables' 5-year high stood at $32.6 million during Q4 2019, with a 5-year trough of $14.1 million in Q1 2022.
- Moreover, its 3-year median value for Non-Current Receivables was $23.1 million (2020), whereas its average is $20.4 million.
- Its Non-Current Receivables has fluctuated over the past 5 years, first spiked by 55.22% in 2019, then tumbled by 39.98% in 2022.
- Over the past 5 years, Ironwood Pharmaceuticals' Non-Current Receivables (Quarterly) stood at $21.0 million in 2018, then surged by 55.22% to $32.6 million in 2019, then fell by 28.21% to $23.4 million in 2020, then increased by 2.55% to $24.0 million in 2021, then plummeted by 39.21% to $14.6 million in 2022.
- Its Non-Current Receivables was $14.6 million in Q4 2022, compared to $14.4 million in Q3 2022 and $14.3 million in Q2 2022.